Actively Recruiting
A Phase 2 Study of CRD-4730 in CPVT
Led by Cardurion Pharmaceuticals, Inc. · Updated on 2026-02-27
12
Participants Needed
9
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
CONDITIONS
Official Title
A Phase 2 Study of CRD-4730 in CPVT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years of age or older and legally an adult
- Confirmed diagnosis of CPVT based on genetic testing for a pathogenic RYR2 mutation and consistent clinical signs
- Able to perform exercise stress test showing frequent premature ventricular contractions (≥10 per minute), ventricular bigeminy, or higher-grade ventricular arrhythmias
- On a stable dose of at least one antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks before screening, unless unable to tolerate such therapy
- Compliant with all contraceptive requirements
You will not qualify if you...
- Clinically significant structural heart disease, heart failure, or coronary artery disease
- Abnormal ECG not explained by CPVT or clinically significant abnormal intervals such as prolonged QT
- History of heart attack, stroke, or transient ischemic attack within 3 months before screening
- ICD implantation or sympathetic nerve denervation within 3 months before screening
- Expected changes in exercise regimen or starting a new exercise program during the study
- History of cancer within past 5 years except certain treated skin or cervical cancers; prior chest radiation is exclusionary
- Abnormal blood pressure or heart rate at screening or Day 1
- Liver impairment defined by elevated liver enzymes or bilirubin at screening unless due to Gilbert syndrome
- Active hepatitis B, hepatitis C, or HIV infection
- Pregnant, breastfeeding, or planning pregnancy during the study or within 3 months after last dose
- Use of additional antiarrhythmic drugs outside stable regimen within 5 half-lives before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Cardurion Investigative Site
San Francisco, California, United States, 94143
Actively Recruiting
2
Cardurion Investigative Site
Morrisville, North Carolina, United States, 27560
Actively Recruiting
3
Cardurion Investigative Site
Houston, Texas, United States, 77030
Actively Recruiting
4
Cardurion Investigative Site
Madison, Wisconsin, United States, 53792
Actively Recruiting
5
Cardurion Investigative Site
Vancouver, British Columbia, Canada, V6Z 1Y6
Actively Recruiting
6
Cardurion Investigative Site
Saint-Herblain, France, 44800
Actively Recruiting
7
Cardurion Investigative Site
Pavia, Pavia, Italy, 27100
Actively Recruiting
8
Cardurion Investigative Site
Amsterdam, North Holland, Netherlands, 1105 AZ
Actively Recruiting
9
Cardurion Investigative Site
Esplugues de Llobregat, Barcelona, Spain, 08950
Actively Recruiting
Research Team
J
Jason Homsy, MD, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here